Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors

/in , /by

Experienced Life Science Operating Leader Joins Board as Company Enters New Phase SOUTH SAN FRANCISCO, Calif. — Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the appointment of Fenel Eloi to its Board of Directors (“Board”). Eloi will also serve on the Board’s Audit Committee. […]

Read more →

Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations

/in , /by

ATLANTA — Axion BioSystems vigorously refutes a recent filing by Agilent Technologies, Inc. (NYSE: A) claiming patent infringement and false advertising. As a recognized biotechnology innovator and owner of numerous patents over 14 years, Axion BioSystems expects its competitors to respect its intellectual property rights, just as Axion respects the intellectual property rights of its […]

Read more →

Curi Bio Launches MantaReady™ 3D Skeletal Muscle Tissue Media

/in , , , /by

Proprietary Medium Provides Longer Culture Times and Stronger Contractile Force SEATTLE — Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of their MantaReady™ Skeletal Muscle Media optimized for human 3D engineered muscle tissue experiments. The proprietary media advances translational in vitro studies by producing tissues with stronger contractile forces, […]

Read more →

CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

/in , , , /by

Cambridge, UK: CN Bio, a leading Organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has today announced that is has appointed Deepak Singh as Vice President of Sales and Marketing. Deepak’s appointment supports the Company’s next phase of commercial development as it expands international operations, product research and development and sales in […]

Read more →

Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed’s HS-001 investigational cell therapy as its first in-human trial commences

/in , , , /by

NOTTINGHAM, England —Albumedix Ltd (‘Albumedix’), Nottingham, United Kingdom, now part of the global life science group Sartorius, and Heartseed Inc (‘Heartseed’), Tokyo, Japan, Tuesday 14th March 2023, announce that Recombumin® is a critical component of Heartseed’s HS-001, an investigational cardiac remuscularization cell therapy which has commenced first in human dosing. Recombumin, an animal and human origin free […]

Read more →

GeminiBio Appoints Industry Veteran Cory Stevenson as Executive Chairman

/in , , , /by

Gemini BioProducts Holding, Inc. (“GeminiBio” or the “Company”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Florida-based healthcare private equity firm, announced the appointment of Cory Stevenson as Executive Chairman of the Board of Directors. Fort Lauderdale, Florida and Sacramento, California – Gemini BioProducts Holding, Inc. (“GeminiBio” or the “Company”), a portfolio company […]

Read more →

RoosterBio and Repligen Collaborate to Advance Scalable Exosome Bioprocessing

/in , , , /by

RoosterBio’s goal, in collaboration with Repligen, is to deliver solutions for manufacturing of exosomes using scalable and low shear technologies that enable cost-effective commercialization of these advanced therapies. FREDERICK, Md. — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, development services, cell engineering, and advanced therapy bioprocess solutions, today announced […]

Read more →

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology

/in , /by

MaxCyte’s Scientific Advisory Board will provide guidance to shape the technical direction of the company’s innovation initiatives focused on the discovery, development and manufacturing of next-generation, cell-based medicines.  ROCKVILLE, MD — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to […]

Read more →

Cytek® Biosciences Introduces New 20-Color AML Panel

/in , , , /by

Optimized for Cytek Cell Analysis Systems; Single-Tube Panel Accelerates Acute Myeloid Leukemia Research and MRD Detection FREMONT, Calif. — Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the launch of a new 20-Color Acute Myeloid Leukemia (AML) Panel. A new single-tube flow panel for the development of AML therapies, this pre-optimized […]

Read more →